Enzymotec Ltd. Announces "New Food Raw Material" Certification for K-REAL(R) Krill Oil in China

MIGDAL HA'EMEQ, Israel, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today its K-REAL® krill oil has received "New Food Raw Material" certification in China.

"We are excited to achieve this important milestone in China for our K-REAL® krill oil," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd. "This certification further illustrates our scientific and product safety commitment to consumers. We believe that China will continue to represent a tremendous growth opportunity for us with a vast portion of the population increasingly consuming premium health and wellness products."

K-REAL® is one of Enzymotec's line of premium omega-3 products, extracted from sustainable Antarctic krill using a unique proprietary extraction process called MSO®. K-REAL® is comprised of naturally occurring phospholipids and triglycerides bound to EPA and DHA, and the powerful antioxidant astaxanthin. K-REAL® has been clinically proven to be significantly more effective than fish oil in increasing the omega-3 index.

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.

Forward Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: a high proportion of the sales of our InFat product is sold to end users by a single company in China; we rely on our Swedish joint venture partner to manufacture InFat, and certain matters related to the joint venture are or, based on communications from our joint venture partner, are the subject of disagreement; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; we are dependent on a single facility that houses the majority of our operations; we may not be able to expand our production or processing capabilities or satisfy growing demand; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; we are currently subject to litigation, and in the future may become subject to additional litigation, regarding intellectual property rights; and other factors discussed under the heading "Risk Factors" in the Company's final prospectus for its initial public offering filed with the Securities and Exchange Commission on September 30, 2013. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: ICR, LLC Katie Turner 646-277-1228 Katie.turner@icrinc.com -or- John Mills 310-954-1105 John.mills@icrinc.comSource:Enzymotec Ltd.